Want to join the conversation?
$ABT 2Q15 10-Q: Working capital was $11.9Bil at June 30, 2015 and $4.7Bil at Dec. 31, 2014. The $7.2Bil increase primarily reflects $4.7Bil of Mylan N.V. ordinary shares held by ABT at June 30, 2015 & proceeds from sale of a portion of shares received in sale of ABT’s developed markets branded generics pharmaceuticals business to Mylan.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.